Le Lézard
Classified in: Health
Subjects: TDS, FVT

NuVasive To Present At The 36th Annual J.P. Morgan Healthcare Conference



SAN DIEGO, Jan. 3, 2018 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, announced today that management will present at the 36th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco on Monday, Jan. 8, 2018, at 1:30 p.m. PT / 4:30 p.m. ET.

NuVasive Logo

A live webcast of the presentation will be available online from the Investor Relations page of the Company's website at www.nuvasive.com. A replay of the presentation will remain available on the website for 30 days after the applicable live webcast.

About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company's portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements

NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products (including the iGA® platform), the Company's ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

 

SOURCE NuVasive, Inc.


These press releases may also interest you

17 jan 2018
Fluke Biomedical, RaySafe and LANDAUER will be demonstrating several new products at the Arab Health Exhibition and Congress held 29 January through 1 February at the Dubai International Convention and Exhibition Centre, Dubai, United Arab Emirates....

17 jan 2018
Today, the U.S. Patent & Trademark Office (PTO) issued a final written decision in Argentum Pharmaceuticals LLC's inter partes review (IPR) against the sole unexpired patent listed as covering Janssen Oncology, Inc.'s ZYTIGA® (abiraterone acetate)...

17 jan 2018
WELL is pleased to announce the launch of its WELL Web Platform for both patients and providers, delivering convenient healthcare anytime, anywhere. WELL's simple, easy to navigate telemedicine platform connects patients worldwide to a global...

17 jan 2018
Safa M. Osman, MD is recognized by Continental Who's Who as a Pinnacle Professional Member in the field of Internal Medicine in recognition of her role as an Internist at Valley Health Internal Medicine.                 Dedicated to the health and...

17 jan 2018
GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced that it will proceed with a Phase 2/3 clinical trial for GC1102 (also known as Hepabig-gene), the company's investigational...

17 jan 2018
Every December, Dr. Leonard's®Healthcare Corp. comes together as a company ? and a family ? to give back to the community and give thanks to veterans with a generous donation to the Veterans of Foreign Wars (VFW) Post #2179 in nearby Port Monmouth,...




News published on 3 january 2018 at 16:02 and distributed by: